Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities

Impact · against what's priced in

The update is largely non-catalytic as the market has already priced in Amgen's growth drivers and key pipeline successes. The only material progression is the completion of MariTide's sleep apnea enrollment, which marginally reduces execution risk for the obesity program the market is currently discounting.

AMGN+0.10

Challenges what's priced in

The price assumes